Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Will reverse in some patients upon drug discontinuance

Publications

Musthafa Hafeesa N, Mufti G, Sivadasanpillai H

Dasatinib-Induced Pulmonary Arterial Hypertension.

JACC. Case reports. 2026:109931

Han HJ, Hong KT, Choi JY, Lee SY, Kang HJ

Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia.

Blood research. 2022;57(1):80-84

Tamura Y, Tamura Y

Dasatinib-induced Pulmonary Hypertension.

Internal medicine (Tokyo, Japan). 2022;61(15):2245-2246

Zeb H, El-Kersh K

Dasatinib-Induced Pulmonary Arterial Hypertension.

American journal of therapeutics. 2020;28(6):e695-e696

Nishimori M, Honjo T, Kaihotsu K, Sone N, Yoshikawa S, Imanishi J, Nakayama K, Emoto N, Iwahashi M

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy.

Case reports in cardiology. 2018;2018:3895197

Makeeva LM, Emelina EI, Gendlin GE, Nikitin IG, Vasyuk YA, Nesvetov VV

[Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].

Kardiologiia. 2017;57(S4):53-60

Özgür Yurttaş N, Eşkazan AE

Dasatinib-induced pulmonary arterial hypertension.

British journal of clinical pharmacology. 2018;84(5):835-845

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

The European respiratory journal. 2017;50(1)

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

American journal of hematology. 2015;90(11):1060-4

Yun S, Anwer F, Vincelette ND

Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.

BMJ case reports. 2014;2014

Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.

The European respiratory journal. 2013;42(3):869-70

Kim JC, Shin SH, Yi HG, Kim SH, Woo SI, Kim DH, Park KS, Kwan J

Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Herz. 2013;38(8):931-3

Sano M, Saotome M, Urushida T, Katoh H, Satoh H, Ohnishi K, Hayashi H

Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.

Internal medicine (Tokyo, Japan). 2012;51(17):2337-40

Breccia M, Efficace F, Alimena G

Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

Leukemia research. 2012;36(7):813-4

Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M

Pulmonary arterial hypertension in patients treated by dasatinib.

Circulation. 2012;125(17):2128-37

Orlandi EM, Rocca B, Pazzano AS, Ghio S

Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

Leukemia research. 2012;36(1):e4-6

Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S

Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.

The European respiratory journal. 2011;38(1):218-20

Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, Brümmendorf TH, Klose H

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

BMC pulmonary medicine. 2011;11:30

Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.

Bone marrow transplantation. 2009;43(12):967-8